The last decade has seen a significant shift and growth in the surgical options available in the management of symptomatic BPH. Not least driven by patients keen to take up options that avoid a general anaesthetic, that are truly ambulatory, allowing a more rapid return to normal activities but also that avoid the risk of significant post-operative complications, including the development of permanent dry ejaculation and/ or impotence. iTind fulfils all these patient desires and now with randomised and long-term data, as well as FDA approval, an expert panel will examine this device, its mechanism of action, reflect upon the body of high-quality data available and discuss the role of iTIND in the surgical armamentarium in 2023.